Skip to main content

OrbiMed Advisors LLC's Form 4/A amendment

Amended

Enliven Therapeutics, Inc. (ELVN) · filed Jul 23, 2021

Accession no.
0000947871-21-000797
Filed
Jul 23, 2021, 5:30 PM ET
Trade date
Jul 16, 2021
Filing delay
7 days
Rule 10b5-1 plan
Not on the form (before 2023)
Original filed
Jul 16, 2021

This filing lists 1 non-derivative transaction. Open-market purchases total $10.0M. It was filed 7 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
OrbiMed Advisors LLCCIK 0001055951Director, 10% Owner
OrbiMed Capital GP VII LLCCIK 0001760648Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 16, 2021Common StockPPurchaseAcquired+1,666,666$6.00+$9,999,9964,199,068IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

These shares of the Issuer's common stock ("Shares") were purchased in the Company's underwritten public offering. The previously reported acquisition of these Shares was inadvertently attributed to OrbiMed Partners Master Fund Limited.

F2

The Shares are held of record by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act, is the managing member of GP VII. GP VII and OrbiMed Advisors may be deemed to have voting and investment power over the securities held by OPI VII and may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the Shares held by OPI VII.

F3

This report on Form 4 is filed by OrbiMed Advisors and GP VII. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VII have designated David Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report on Form 4 shall not be deemed an admission that any of the Reporting Persons, or David Bonita, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Remarks

This Amendment is being filed solely to correct the information regarding the ownership form and nature of indirect beneficial ownership for the previously reported transaction.

Read the full filing on SEC EDGAR (opens in a new tab)